Cargando…

Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting

INTRODUCTION: Studies on treatment adherence to glucose‐lowering drugs among patients with type 2 diabetes (T2D) including concomitant treatment for other cardiovascular risk factors are scarce. We aimed to estimate the prevalence of good adherence to all medications used to control diabetes, hypert...

Descripción completa

Detalles Bibliográficos
Autores principales: Orozco‐Beltrán, Domingo, Cinza‐Sanjurjo, Sergio, Escribano‐Serrano, José, López‐Simarro, Flora, Fernández, Gonzalo, Gómez García, Antón, Ferreira de Campos, Karine, Cedenilla Horcajuelo, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917867/
https://www.ncbi.nlm.nih.gov/pubmed/34964310
http://dx.doi.org/10.1002/edm2.320
_version_ 1784668639160434688
author Orozco‐Beltrán, Domingo
Cinza‐Sanjurjo, Sergio
Escribano‐Serrano, José
López‐Simarro, Flora
Fernández, Gonzalo
Gómez García, Antón
Ferreira de Campos, Karine
Cedenilla Horcajuelo, Marta
author_facet Orozco‐Beltrán, Domingo
Cinza‐Sanjurjo, Sergio
Escribano‐Serrano, José
López‐Simarro, Flora
Fernández, Gonzalo
Gómez García, Antón
Ferreira de Campos, Karine
Cedenilla Horcajuelo, Marta
author_sort Orozco‐Beltrán, Domingo
collection PubMed
description INTRODUCTION: Studies on treatment adherence to glucose‐lowering drugs among patients with type 2 diabetes (T2D) including concomitant treatment for other cardiovascular risk factors are scarce. We aimed to estimate the prevalence of good adherence to all medications used to control diabetes, hypertension and dyslipidemia and to analyse cardiometabolic control and its associated factors in T2D patients in the primary care (PC) setting. METHODS: Observational, retrospective study conducted in adult patients with T2D who were followed in the PC setting in Spain. Patients were classified as adherent in a particular category if the summary of the proportion of days covered (PDC) for a particular medication category was ≥80% and were considered globally adherent if the PDC was ≥80% for each of the 3 medication categories. RESULTS: A total of 457 evaluable patients were recruited, among which 321 patients (70.3%, 95% CI 65.8 to 74.4) were adherent to the three drug categories. The proportion of patients controlled for the 3 cardiometabolic risk factors was 31% according to the contemporary clinical practice guideline criteria, 58% according to investigator judgment and 36% when the objective for HbA1c was individualized. In a multivariate analysis, presenting comorbidities was associated with a lower likelihood of showing adequate control of dyslipidemia (odds ratio [OR] 0.25, 95% CI, 0.16–0.40) and the three cardiometabolic factors as a whole (OR 0.43, 95% CI 0.26–0.70). In a post hoc analysis, therapeutic inertia was found to be greater for dyslipidemia and hypertension than for T2D. CONCLUSIONS: Despite a relatively high adherence to all medications for treating diabetes, hypertension and dyslipidemia in patients with T2D in the PC setting in Spain, the control of cardiometabolic risk factors as a whole is far from optimal. This could be related, at least in part, to the high frequency of comorbidity of these patients.
format Online
Article
Text
id pubmed-8917867
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89178672022-03-18 Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting Orozco‐Beltrán, Domingo Cinza‐Sanjurjo, Sergio Escribano‐Serrano, José López‐Simarro, Flora Fernández, Gonzalo Gómez García, Antón Ferreira de Campos, Karine Cedenilla Horcajuelo, Marta Endocrinol Diabetes Metab Original Research Articles INTRODUCTION: Studies on treatment adherence to glucose‐lowering drugs among patients with type 2 diabetes (T2D) including concomitant treatment for other cardiovascular risk factors are scarce. We aimed to estimate the prevalence of good adherence to all medications used to control diabetes, hypertension and dyslipidemia and to analyse cardiometabolic control and its associated factors in T2D patients in the primary care (PC) setting. METHODS: Observational, retrospective study conducted in adult patients with T2D who were followed in the PC setting in Spain. Patients were classified as adherent in a particular category if the summary of the proportion of days covered (PDC) for a particular medication category was ≥80% and were considered globally adherent if the PDC was ≥80% for each of the 3 medication categories. RESULTS: A total of 457 evaluable patients were recruited, among which 321 patients (70.3%, 95% CI 65.8 to 74.4) were adherent to the three drug categories. The proportion of patients controlled for the 3 cardiometabolic risk factors was 31% according to the contemporary clinical practice guideline criteria, 58% according to investigator judgment and 36% when the objective for HbA1c was individualized. In a multivariate analysis, presenting comorbidities was associated with a lower likelihood of showing adequate control of dyslipidemia (odds ratio [OR] 0.25, 95% CI, 0.16–0.40) and the three cardiometabolic factors as a whole (OR 0.43, 95% CI 0.26–0.70). In a post hoc analysis, therapeutic inertia was found to be greater for dyslipidemia and hypertension than for T2D. CONCLUSIONS: Despite a relatively high adherence to all medications for treating diabetes, hypertension and dyslipidemia in patients with T2D in the PC setting in Spain, the control of cardiometabolic risk factors as a whole is far from optimal. This could be related, at least in part, to the high frequency of comorbidity of these patients. John Wiley and Sons Inc. 2021-12-28 /pmc/articles/PMC8917867/ /pubmed/34964310 http://dx.doi.org/10.1002/edm2.320 Text en © 2021 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Articles
Orozco‐Beltrán, Domingo
Cinza‐Sanjurjo, Sergio
Escribano‐Serrano, José
López‐Simarro, Flora
Fernández, Gonzalo
Gómez García, Antón
Ferreira de Campos, Karine
Cedenilla Horcajuelo, Marta
Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting
title Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting
title_full Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting
title_fullStr Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting
title_full_unstemmed Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting
title_short Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting
title_sort adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917867/
https://www.ncbi.nlm.nih.gov/pubmed/34964310
http://dx.doi.org/10.1002/edm2.320
work_keys_str_mv AT orozcobeltrandomingo adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting
AT cinzasanjurjosergio adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting
AT escribanoserranojose adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting
AT lopezsimarroflora adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting
AT fernandezgonzalo adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting
AT gomezgarciaanton adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting
AT ferreiradecamposkarine adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting
AT cedenillahorcajuelomarta adherencecontrolofcardiometabolicfactorsandtherapeuticinertiainpatientswithtype2diabetesintheprimarycaresetting